#USA #GC Biopharma #Tampa #ALYGLO #IIR Program

GC Biopharma Shines at the 2025 CIIC Fall Conference

Overview

On September 26-28, 2025, GC Biopharma USA, Inc. participated in the Consortium of Independent Immunology Clinics (CIIC) Fall Conference in Tampa, Florida, serving as the exclusive Science to Solutions Partner. This conference was aimed at fostering collaborative discussions among independent immunology practices, aiming to interface scientific advancements with practical applications in IVIG treatments and patient care.

Highlighting IVIG and Investigator-Initiated Research

Suzanne Strasters, MSN, FNP-C, IgCN, who oversees Clinical Education at GC Biopharma, delivered a presentation focused on the company’s extensive product pipeline and the Investigator-Initiated Research (IIR) Program. This initiative underlines GC Biopharma’s dedication to bolstering independent research initiatives that deepen medical knowledge regarding immunoglobulin therapies.

"Being the Science to Solutions partner at CIIC reflects GC Biopharma's dedication to education, collaboration, and supporting clinicians in delivering high-quality patient care," stated Strasters.

Creating Unique Opportunities for Dialogue

The CIIC Fall Conference is designed to promote significant scientific dialogues within a setting that limits sponsor presence, ensuring that discussions remain focused on innovation and real-world applications. This distinctive environment allows industry leaders and practitioners to engage meaningfully, enhancing collaboration in developing new treatment insights.

Manufacturing Excellence with ALYGLO®

GC Biopharma brings over 50 years of expertise in the plasma protein manufacturing field, continuously aiming to elevate standards within IVIG therapies. Their product, ALYGLO®, employs a novel cation exchange (CEX) chromatography known as G-XI™ Technology. This innovative process effectively reduces coagulation factor XIa (FXIa) to undetectable levels, addressing long-standing concerns within the immunoglobulin community about FXIa’s presence in IVIG.

ALYGLO® has received FDA approval for treating primary humoral immunodeficiency (PI) in adults aged 17 and above and represents GC Biopharma's commitment to quality healthcare. This product is also recognized for its adherence to rigorous safety standards and is distributed across more than 50 countries.

Commitment to Advancing Immunoglobulin Treatments

GC Biopharma's participation in the CIIC Fall Conference is part of its broader commitment to support and promote independent research that significantly enhances our understanding of the health impacts of immunoglobulin therapies. Their initiatives, particularly the IIR Program, are designed to empower healthcare professionals and researchers, thereby paving the way for further breakthroughs in treating primary immunodeficiencies.

Conclusion

As a key player in the field of plasma-derived products and immunoglobulin treatment, GC Biopharma USA is not only devoted to advancing therapeutic options but is also dedicated to supporting the scientific community through collaboration, education, and research initiatives. With innovative products like ALYGLO® and a strong focus on independent research, GC Biopharma is poised to continue making significant contributions to patient care and enhancing the treatment landscape for immunodeficiencies.

For more information on ALYGLO and the G-XI™ Technology, please visit www.alyglo.com. Likewise, for details on GC Biopharma's ongoing research initiatives, you can explore www.gcbiopharmausa.com.